10-Q: DataMeds AI Reports Steep Revenue Drop, Net Loss

DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a significant decrease in net revenues for the first six months of 2026 compared to the prior year, primarily due to liquidity constraints impacting its distribution business, alongside a substantial net loss.

Summary

• DataMeds AI, Inc. (formerly Wellgistics Health, Inc.) reported a substantial net loss of $18,363,225 for the three months ended June 30, 2026, and $26,105,822 for the six months ended June 30, 2026.
• Net revenues decreased significantly, with a 77.2% drop for the three-month period and an 82.1% drop for the six-month period, largely attributed to liquidity constraints affecting the distribution segment.
• The company's gross margin improved to 10.2% for the three months and 10.6% for the six months ended June 30, 2026, from 6.5% and 6.4% respectively in the prior year, driven by a higher contribution from the pharmacy retail segment.
• General and administrative expenses increased by 45.2% for the three-month period due to non-recurring compensation charges and higher stock-based compensation, though they decreased significantly for the six-month period due to a large one-time stock-based compensation expense in the prior year.
• The company faces substantial doubt about its ability to continue as a going concern, with a working capital deficit of $33,781,185 as of June 30, 2026, and has been actively pursuing capital raises.
• A proposed transaction involving the acquisition or licensing of intellectual property assets from EOS Technology Holdings, Inc., Scilex Holding Company, and Datavault AI Inc., and acquiring a controlling interest in Tollo Health, LLC, is underway, subject to definitive agreements and approvals.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to significant revenue declines, substantial net losses, and ongoing liquidity concerns, despite recent financing efforts and a proposed strategic transaction.

Positives

• Gross margin percentage improved to 10.2% for Q2 2026 and 10.6% for H1 2026, up from 6.5% and 6.4% in the prior year periods, respectively, due to a higher contribution from the more profitable pharmacy retail segment.
• Pharmacy retail sales saw significant growth, increasing to $1,590,367 for the three months ended June 30, 2026, from $77,756 in the prior year period, and to $2,724,783 for the six months ended June 30, 2026, from $192,432 in the prior year period.
• The company successfully completed a reverse stock split on May 26, 2026, which helped it regain compliance with Nasdaq's minimum bid price requirement.
• The company entered into a new Note Purchase Agreement on May 27, 2026, refinancing outstanding convertible notes and raising new capital, though it resulted in a significant loss on extinguishment of debt.

Negatives

• Net revenues experienced a sharp decline, falling by 77.2% to $1,779,860 for the three months ended June 30, 2026, and by 82.1% to $3,339,423 for the six months ended June 30, 2026, compared to the prior year periods.
• The company reported a substantial net loss of $18,363,225 for the three months and $26,105,822 for the six months ended June 30, 2026.
• The company has a significant accumulated deficit of $137,137,512 as of June 30, 2026.
• There is substantial doubt about the company's ability to continue as a going concern within twelve months from the issuance date of the financial statements.
• The company incurred a significant loss on extinguishment of debt of $8,881,694 for the six months ended June 30, 2026, related to the refinancing of convertible promissory notes.
• The distribution business within Wellgistics, LLC experienced a significant decline in revenue due to liquidity constraints that limited the company's ability to procure and fulfill product orders.

Risks

• The company faces substantial doubt about its ability to continue as a going concern due to significant net losses, accumulated deficit, and negative working capital.
• The company is not in compliance with Nasdaq Listing Rule 5550(b)(1) requiring a minimum stockholders equity of $2.5 million and has until October 12, 2026, to evidence compliance, or its stock may be delisted.
• Liquidity constraints have significantly impacted the company's ability to procure and fulfill product orders in its distribution business.
• The proposed transaction with EOS, Scilex, Datavault, and HealthBridge Advisors is subject to numerous conditions, including definitive agreements, approvals, and financing availability, with no assurance of consummation.
• The company is involved in several legal proceedings, including an arbitration demand for accounting services and a lawsuit filed by a former CEO, which could result in material adverse effects.
• The company has received demand letters from various vendors for approximately $4.3 million in payments, with $1.5 million not yet recorded as liabilities.

Future Outlook

The company is actively pursuing multiple initiatives to address liquidity and going concern uncertainties, including financing transactions and strategic initiatives. A proposed transaction involving intellectual property acquisition and a controlling interest in Tollo Health, LLC is in progress, subject to definitive agreements and approvals. Management expects to expand wholesale operations and leverage its digital pharmacy platform to improve patient access and outcomes.

Management Comments

• Management is actively pursuing multiple initiatives to address the Company's liquidity position and going concern uncertainty.
• Management evaluated the decline in the distribution business and believes the Company has sufficient plans in place, including financing transactions and strategic initiatives, to address its underlying causes.
• Management concluded that the carrying value of goodwill and other intangible assets attributable to the distribution business was not impaired as of June 30, 2026.
• Management has implemented or is in the process of implementing measures to remediate material weaknesses in internal control over financial reporting, including hiring additional accounting personnel and enhancing internal review procedures.

Industry Context

StockSavvy.ai notes that DataMeds AI operates in the highly competitive and regulated pharmaceutical services sector. The reported revenue decline in distribution, attributed to liquidity constraints, highlights the capital-intensive nature of this segment. The company's strategic focus on a digital pharmacy ecosystem and specialty-lite therapies aligns with broader industry trends towards patient-centric care and data utilization, but faces significant execution and financial hurdles.

Comparison to Industry Standards

• The company's revenue decline of over 80% in its distribution segment for the first six months of 2026 is significantly worse than typical industry performance, where stable or moderate growth is generally expected for established distributors.
• The reported gross margin improvement to over 10% is positive, but this is largely due to a shift towards higher-margin pharmacy retail sales, which is a smaller portion of the overall revenue. The distribution segment's gross margin is likely suppressed by the revenue decline.
• The company's substantial net loss and accumulated deficit are concerning and indicate a financial performance far below industry standards for companies aiming for sustainable growth. Many competitors in the pharmaceutical services space are profitable or have clearer paths to profitability.
• The company's reliance on frequent debt and equity financings to sustain operations is a common characteristic of early-stage or distressed companies, but it deviates from the more stable capital structures of established industry players.

Management Changes

Legal Proceedings

• Blythe Global Advisors, LLC has filed a demand for arbitration against the Company and its Chairman of the Board for breach of contract, seeking $377,947 for accounting services.
• The Company's subsidiaries have sued Blythe Global Advisors, LLC for improper UCC-1 filings, tortious interference, slander of title, and state RICO violations.
• Wellgistics, LLC is a defendant in a lawsuit filed by Lifsa Drugs LLC, alleging non-payment for pharmaceutical products, seeking approximately $420,460 in damages.
• Brian Norton, former CEO, filed suit against the Company in Delaware seeking monetary damages and shares of common stock related to the sale of his membership interests in Wellgistics, LLC.
• The Company initiated litigation against certain former officers and/or directors for breach of fiduciary duty, breach of contract, and other claims, with additional claims for misrepresentations and omissions related to an acquisition.

Related Party Transactions

• Accounts payable to Scietech, LLC, where a significant investor is the spouse of a director, was $25,500 as of June 30, 2026.
• Consulting fees incurred to Fortitude Advisors, LLC (a related party effective May 20, 2026) were $119,995 for the three months and $169,995 for the six months ended June 30, 2026.
• A receivable of $21,868 was due from Tollo Health, LLC (a related party effective May 20, 2026) as of June 30, 2026.
• Prior related party transactions with Integra Pharma Solutions, LLC, Nomad Capital LLC, Cingo Solutions, and RxERP were noted for the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders face continued uncertainty regarding the company's going concern status and potential stock delisting from Nasdaq.
• The significant revenue decline and liquidity issues may impact the company's ability to meet its obligations to suppliers and creditors.
• Employees may be concerned about job security given the company's financial performance and ongoing restructuring efforts.
• Customers of the distribution business may experience disruptions due to liquidity constraints affecting product procurement and fulfillment.

Next Steps

• Negotiate and execute definitive agreements for the proposed transaction with EOS, Scilex, Datavault, and HealthBridge Advisors.
• Obtain necessary stockholder and other approvals for the proposed transaction.
• Secure required financing for the proposed transaction.
• Evidence compliance with Nasdaq's minimum stockholders equity requirement by October 12, 2026.
• Continue to pursue additional sources of capital, including equity financing, debt arrangements, and strategic partnerships.
• Implement remediation measures for material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The filing indicates severe financial distress, including a sharp decline in revenues, substantial net losses, a significant accumulated deficit, and substantial doubt about the company's ability to continue as a going concern. While there are ongoing financing efforts and a proposed strategic transaction, the risks associated with these initiatives and the company's current financial condition outweigh potential positives, suggesting a sell recommendation for investors.

Keywords

pharmaceutical distribution, specialty pharmacy, healthcare technology, convertible notes, financing, going concern, revenue decline, net loss